Trials / Unknown
UnknownNCT02267902
Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229
A Phase I, Open-Label, 2-Part Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism and Excretion of DA-1229 in Healthy Male Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The objectives of this study are to evaluate the absolute bioavailability, and absorption and excretion of DA-1229, an IMP in clinical assessment for the treatment of T2DM. The oral and IV PK of DA-1229 will also be evaluated. The metabolism of DA-1229 may also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-1229 |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2014-10-20
- Last updated
- 2014-10-20
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02267902. Inclusion in this directory is not an endorsement.